Back to MPT Database

Dolutegravir (DTG) + Rilpivirine (RPV) + Acyclovir + Ethinyl Estradiol + Etonogestrel IVR

Development Stage:

Preclinical – Advanced (Pre2)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Developer:

  • Auritec Pharmaceuticals

Funding:

  • Nat. Institute Allergy & Infect. Diseases (NIAID)

Funding Mechanism:

NIAID: R61, R33

Active Ingredient(s):

  • Acyclovir
  • Dolutegravir
  • Etonogestrel
  • Ethinyl Estradiol
  • Rilpivirine

Product Indication(s):

  • HIV
  • HSV-2
  • Pregnancy

Back to MPT Database